Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8707145 | Oral Oncology | 2018 | 9 Pages |
Abstract
HRAS mutant cells are resistant to PI3K inhibition and our findings suggest the involvement of a signalling intersection of the MAPK and PI3K pathways at the level of ERK-TSC2, leading to persistent mTOR activity. mTOR inhibition alone or in combination with MAPK pathway inhibition may be a promising therapeutic strategy for this subset of HNSCC tumors.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Dentistry, Oral Surgery and Medicine
Authors
Kara M. Ruicci, Nicole Pinto, Mohammed I. Khan, John Yoo, Kevin Fung, Danielle MacNeil, Joe S. Mymryk, John W. Barrett, Anthony C. Nichols,